JP2018536687A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536687A5 JP2018536687A5 JP2018530001A JP2018530001A JP2018536687A5 JP 2018536687 A5 JP2018536687 A5 JP 2018536687A5 JP 2018530001 A JP2018530001 A JP 2018530001A JP 2018530001 A JP2018530001 A JP 2018530001A JP 2018536687 A5 JP2018536687 A5 JP 2018536687A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- phenyl
- alkoxy
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 45
- 125000005843 halogen group Chemical group 0.000 claims 22
- 125000003545 alkoxy group Chemical group 0.000 claims 21
- 125000001188 haloalkyl group Chemical group 0.000 claims 20
- 125000004438 haloalkoxy group Chemical group 0.000 claims 19
- 125000001424 substituent group Chemical group 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 125000004076 pyridyl group Chemical group 0.000 claims 13
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000002393 azetidinyl group Chemical group 0.000 claims 6
- 125000002757 morpholinyl group Chemical group 0.000 claims 6
- -1 or benzodioxyl Chemical group 0.000 claims 6
- 125000004193 piperazinyl group Chemical group 0.000 claims 6
- 125000003386 piperidinyl group Chemical group 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000000842 isoxazolyl group Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000001544 thienyl group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 3
- 125000002971 oxazolyl group Chemical group 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 3
- 125000004306 triazinyl group Chemical group 0.000 claims 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000004441 haloalkylsulfonyl group Chemical group 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- ZJMQIDCUWFQBBS-OAQYLSRUSA-N 1-(4-chloro-2-fluorophenyl)-3-[(3R)-1-[4-[2-(methanesulfonamido)pyridin-3-yl]phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)NC1=NC=CC=C1C1=CC=C(C=C1)N1CCC[C@@H](NC(=O)NC2=C(F)C=C(Cl)C=C2)C1=O ZJMQIDCUWFQBBS-OAQYLSRUSA-N 0.000 claims 1
- QQPVLMVWMKXQHE-XMMPIXPASA-N 1-(4-chloro-2-fluorophenyl)-3-[(3R)-1-[4-[3-(methanesulfonamidomethyl)phenyl]phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)NCc1cccc(c1)-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(Cl)cc2F)C1=O QQPVLMVWMKXQHE-XMMPIXPASA-N 0.000 claims 1
- OHLYBNSPTDBWII-OAQYLSRUSA-N 1-(4-chlorophenyl)-3-[(3R)-1-[2-fluoro-4-(2-methylsulfonylphenyl)phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)C1=C(C=CC=C1)C1=CC(F)=C(C=C1)N1CCC[C@@H](NC(=O)NC2=CC=C(Cl)C=C2)C1=O OHLYBNSPTDBWII-OAQYLSRUSA-N 0.000 claims 1
- UBOJUPGIJLMJCN-JOCHJYFZSA-N 1-(4-chlorophenyl)-3-[(3R)-1-[4-(2-methylsulfonylphenyl)phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)C1=C(C=CC=C1)C1=CC=C(C=C1)N1CCC[C@@H](NC(=O)NC2=CC=C(Cl)C=C2)C1=O UBOJUPGIJLMJCN-JOCHJYFZSA-N 0.000 claims 1
- LOSIFPMBGPRRNJ-HSZRJFAPSA-N 1-(4-chlorophenyl)-3-[(3R)-1-[4-[2-(methanesulfonamido)phenyl]phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)NC1=C(C=CC=C1)C1=CC=C(C=C1)N1CCC[C@@H](NC(=O)NC2=CC=C(Cl)C=C2)C1=O LOSIFPMBGPRRNJ-HSZRJFAPSA-N 0.000 claims 1
- AJPPVEUXDAUQMA-OAQYLSRUSA-N 1-(4-chlorophenyl)-3-[(3R)-1-[4-[2-(methanesulfonamido)pyridin-3-yl]phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)NC1=NC=CC=C1C1=CC=C(C=C1)N1CCC[C@@H](NC(=O)NC2=CC=C(Cl)C=C2)C1=O AJPPVEUXDAUQMA-OAQYLSRUSA-N 0.000 claims 1
- LHCDRRGUOGKMRW-JOCHJYFZSA-N 1-(5-chloropyridin-2-yl)-3-[(3R)-1-[4-[2-(methanesulfonamidomethyl)phenyl]phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)NCc1ccccc1-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(Cl)cn2)C1=O LHCDRRGUOGKMRW-JOCHJYFZSA-N 0.000 claims 1
- AIDAYUXXQQPICM-OAQYLSRUSA-N 1-(6-chloropyridin-3-yl)-3-[(3R)-1-[4-[2-(methanesulfonamido)phenyl]phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)Nc1ccccc1-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(Cl)nc2)C1=O AIDAYUXXQQPICM-OAQYLSRUSA-N 0.000 claims 1
- SMTNDFPSTGCTRT-JOCHJYFZSA-N 1-(6-chloropyridin-3-yl)-3-[(3R)-1-[4-[2-(methanesulfonamidomethyl)phenyl]phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)NCc1ccccc1-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(Cl)nc2)C1=O SMTNDFPSTGCTRT-JOCHJYFZSA-N 0.000 claims 1
- SPCFTOQYHGQAQX-JOCHJYFZSA-N 1-(6-chloropyridin-3-yl)-3-[(3R)-1-[4-[3-(methanesulfonamidomethyl)phenyl]phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)NCc1cccc(c1)-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(Cl)nc2)C1=O SPCFTOQYHGQAQX-JOCHJYFZSA-N 0.000 claims 1
- LBKZAJLYIZAXHD-HXUWFJFHSA-N 1-[(3R)-1-[4-[2-(methanesulfonamido)phenyl]phenyl]-2-oxopiperidin-3-yl]-3-(5-methyl-1,2-oxazol-3-yl)urea Chemical compound Cc1cc(NC(=O)N[C@@H]2CCCN(C2=O)c2ccc(cc2)-c2ccccc2NS(C)(=O)=O)no1 LBKZAJLYIZAXHD-HXUWFJFHSA-N 0.000 claims 1
- HIRCZQRIKKQTKV-HSZRJFAPSA-N 1-[(3R)-1-[4-[2-(methanesulfonamido)phenyl]phenyl]-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea Chemical compound CS(=O)(=O)Nc1ccccc1-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(cc2)C(F)(F)F)C1=O HIRCZQRIKKQTKV-HSZRJFAPSA-N 0.000 claims 1
- VQOULAYTSCHUII-OAQYLSRUSA-N 1-[(3R)-1-[4-[2-(methanesulfonamido)phenyl]phenyl]-2-oxopiperidin-3-yl]-3-[5-(trifluoromethyl)pyridin-2-yl]urea Chemical compound CS(=O)(=O)Nc1ccccc1-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(cn2)C(F)(F)F)C1=O VQOULAYTSCHUII-OAQYLSRUSA-N 0.000 claims 1
- POGQSYOBRNXNIG-OAQYLSRUSA-N 1-[(3R)-1-[4-[2-(methanesulfonamido)phenyl]phenyl]-2-oxopiperidin-3-yl]-3-[6-(trifluoromethyl)pyridin-3-yl]urea Chemical compound CS(=O)(=O)Nc1ccccc1-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(nc2)C(F)(F)F)C1=O POGQSYOBRNXNIG-OAQYLSRUSA-N 0.000 claims 1
- HBBUWMWLEWOSFT-OAQYLSRUSA-N 1-[(3R)-1-[4-[2-(methanesulfonamido)pyridin-3-yl]phenyl]-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea Chemical compound CS(=O)(=O)NC1=NC=CC=C1C1=CC=C(C=C1)N1C([C@@H](CCC1)NC(NC1=CC=C(C=C1)C(F)(F)F)=O)=O HBBUWMWLEWOSFT-OAQYLSRUSA-N 0.000 claims 1
- VSVOTKNFGHDFPB-XMMPIXPASA-N 1-[(3R)-1-[4-[2-(methanesulfonamidomethyl)phenyl]phenyl]-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea Chemical compound CS(=O)(=O)NCc1ccccc1-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(cc2)C(F)(F)F)C1=O VSVOTKNFGHDFPB-XMMPIXPASA-N 0.000 claims 1
- VXJDKOGERHOGJG-HXUWFJFHSA-N 1-[(3R)-1-[5-(2-fluorophenyl)pyridin-2-yl]-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea Chemical compound FC1=C(C=CC=C1)C=1C=CC(=NC=1)N1C([C@@H](CCC1)NC(NC1=CC=C(C=C1)C(F)(F)F)=O)=O VXJDKOGERHOGJG-HXUWFJFHSA-N 0.000 claims 1
- MUSFHYDVTYUBGU-OAQYLSRUSA-N 1-[(3R)-1-[5-[2-(methanesulfonamido)phenyl]pyridin-2-yl]-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea Chemical compound CS(=O)(=O)NC1=C(C=CC=C1)C=1C=CC(=NC=1)N1C([C@@H](CCC1)NC(NC1=CC=C(C=C1)C(F)(F)F)=O)=O MUSFHYDVTYUBGU-OAQYLSRUSA-N 0.000 claims 1
- YELGTUQEHZEBDY-JOCHJYFZSA-N 1-[(3R)-1-[6-[2-(methanesulfonamido)phenyl]pyridin-3-yl]-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea Chemical compound CS(=O)(=O)NC1=C(C=CC=C1)C1=CC=C(C=N1)N1C([C@@H](CCC1)NC(NC1=CC=C(C=C1)C(F)(F)F)=O)=O YELGTUQEHZEBDY-JOCHJYFZSA-N 0.000 claims 1
- XXTALGDGUPQNQI-OAQYLSRUSA-N 2-[4-[(3R)-3-[(4-chlorophenyl)carbamoylamino]-2-oxopiperidin-1-yl]-3-fluorophenyl]benzamide Chemical compound NC(=O)c1ccccc1-c1ccc(N2CCC[C@@H](NC(=O)Nc3ccc(Cl)cc3)C2=O)c(F)c1 XXTALGDGUPQNQI-OAQYLSRUSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001269 cardiogenic effect Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562265885P | 2015-12-10 | 2015-12-10 | |
| US62/265,885 | 2015-12-10 | ||
| PCT/US2016/065504 WO2017100390A1 (en) | 2015-12-10 | 2016-12-08 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536687A JP2018536687A (ja) | 2018-12-13 |
| JP2018536687A5 true JP2018536687A5 (https=) | 2020-01-23 |
| JP6811241B2 JP6811241B2 (ja) | 2021-01-13 |
Family
ID=57590898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530001A Active JP6811241B2 (ja) | 2015-12-10 | 2016-12-08 | ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10717708B2 (https=) |
| EP (1) | EP3414227B1 (https=) |
| JP (1) | JP6811241B2 (https=) |
| KR (1) | KR102772801B1 (https=) |
| CN (1) | CN108368046B (https=) |
| AU (1) | AU2016366211B2 (https=) |
| BR (1) | BR112018011046A2 (https=) |
| CA (1) | CA3007972A1 (https=) |
| EA (1) | EA034227B1 (https=) |
| ES (1) | ES2901471T3 (https=) |
| IL (1) | IL259791B (https=) |
| MX (1) | MX386387B (https=) |
| SG (1) | SG11201804589TA (https=) |
| WO (1) | WO2017100390A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018005756A (es) * | 2015-11-24 | 2018-08-01 | Squibb Bristol Myers Co | Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas. |
| JP6811241B2 (ja) | 2015-12-10 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト |
| EP3634958B1 (en) | 2017-06-09 | 2021-07-21 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| WO2018227065A1 (en) * | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| KR102615099B1 (ko) | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| KR102615095B1 (ko) * | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 효능제 |
| KR102803660B1 (ko) * | 2018-03-05 | 2025-05-02 | 브리스톨-마이어스 스큅 컴퍼니 | 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제 |
| AR114383A1 (es) * | 2018-03-09 | 2020-08-26 | Gruenenthal Gmbh | Piperidinas o piperidonas sustituidas con urea y fenilo |
| CN113166134B (zh) | 2018-11-26 | 2024-06-14 | 百时美施贵宝公司 | 作为甲酰肽2受体激动剂的吡咯烷酮衍生物 |
| EP3986903B1 (en) * | 2019-06-18 | 2023-05-10 | Bristol-Myers Squibb Company | Biaryl dialkyl phosphine oxide fpr2 agonists |
| EP3789378A1 (en) * | 2019-09-06 | 2021-03-10 | Grünenthal GmbH | Piperidines or piperidones substituted with urea and heteroaryl |
| CA3185263A1 (en) | 2020-07-09 | 2022-01-13 | James A. Johnson | Pyrazolone formyl peptide 2 receptor agonists |
| KR20230051525A (ko) * | 2020-08-12 | 2023-04-18 | 브리스톨-마이어스 스큅 컴퍼니 | 옥소피롤리딘 우레아 fpr2 효능제 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002060859A2 (en) | 2000-12-20 | 2002-08-08 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| WO2006063113A2 (en) * | 2004-12-07 | 2006-06-15 | Portola Pharmaceuticals, Inc. | Ureas as factor xa inhibitors |
| KR102223384B1 (ko) * | 2013-03-06 | 2021-03-05 | 알러간, 인코포레이티드 | 피부 질환 치료용 포르밀 펩티드 수용체 2의 항진제의 용도 |
| NZ720508A (en) | 2013-11-28 | 2019-03-29 | Kyorin Seiyaku Kk | Urea derivative or pharmacologically acceptable salt thereof |
| JP6746614B2 (ja) | 2015-05-27 | 2020-08-26 | 杏林製薬株式会社 | ウレア誘導体、またはその薬理学的に許容される塩 |
| WO2016189876A1 (en) | 2015-05-27 | 2016-12-01 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
| MX2018005756A (es) | 2015-11-24 | 2018-08-01 | Squibb Bristol Myers Co | Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas. |
| JP6811241B2 (ja) | 2015-12-10 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト |
| WO2018227065A1 (en) | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| EP3634958B1 (en) | 2017-06-09 | 2021-07-21 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| KR102615099B1 (ko) | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| KR102615095B1 (ko) | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 효능제 |
-
2016
- 2016-12-08 JP JP2018530001A patent/JP6811241B2/ja active Active
- 2016-12-08 AU AU2016366211A patent/AU2016366211B2/en not_active Ceased
- 2016-12-08 CN CN201680072467.4A patent/CN108368046B/zh active Active
- 2016-12-08 US US15/776,933 patent/US10717708B2/en active Active
- 2016-12-08 BR BR112018011046A patent/BR112018011046A2/pt active Search and Examination
- 2016-12-08 EP EP16816564.5A patent/EP3414227B1/en active Active
- 2016-12-08 WO PCT/US2016/065504 patent/WO2017100390A1/en not_active Ceased
- 2016-12-08 EA EA201891143A patent/EA034227B1/ru not_active IP Right Cessation
- 2016-12-08 KR KR1020187019246A patent/KR102772801B1/ko active Active
- 2016-12-08 CA CA3007972A patent/CA3007972A1/en not_active Abandoned
- 2016-12-08 SG SG11201804589TA patent/SG11201804589TA/en unknown
- 2016-12-08 ES ES16816564T patent/ES2901471T3/es active Active
- 2016-12-08 MX MX2018006635A patent/MX386387B/es unknown
-
2018
- 2018-06-04 IL IL259791A patent/IL259791B/en unknown
-
2020
- 2020-06-11 US US16/898,889 patent/US11530183B2/en active Active